Current therapeutic modalities for Parkinsonian pathology operate primarily on isolated symptomatic management, failing to address the cascading systemic degradation of the overarching neural architecture. This manuscript proposes a comprehensive theoretical framework replacing singular molecular targeting with a sequential, multi-phase biochemical stabilization protocol to systematically resolve the underlying cellular friction: Phase I (Proteostatic Clearance): Utilizes N-Acetyl-L-Leucine and Spermidine to dissolve alpha-synuclein aggregates and trigger the autophagic recycling of misfolded proteins. Phase II (Bioenergetic Induction): Utilizes Nicotinamide Riboside (NR) and CoQ10 + PQQ to restore the mitochondrial membrane potential required for sustained synaptic transmission. Phase III (Kinetic Resolution): Utilizes Standardized L-Dopa (Mucuna pruriens) and N-Acetyl Cysteine to restore dopaminergic signal resolution and clear localized oxidative microenvironments. Phase IV (Neuroinflammatory Attenuation): Utilizes Liposomal Glutathione and High-Dose Omega-3 (DHA) to calibrate the microglial response and restore the structural fluidity of neuronal lipid bilayers.
No takes yet. Share an insight, caveat, or question.
Rayce J'Ro (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: